


## SL-35: Oncology Phenotypic Screening. Macrocycles.

Phenotypic screening is a firmly established technology that has contributed to the identification of valuable therapeutic agents in oncology drug discovery [1]. For example, in colon cancer multiple etiological pathways are responsible for disease onset and development [2].

At ASINEX, we have evaluated the susceptibility of several cancer cell lines (i.e. RKO, HCT116, Molt-4, Rs4-11, U937, A549, H1568, H23, PANC1, A2780) to an array of peptidic and non-peptidic macrocycles and identified a series of compounds that kill cancer cells at  $\mu\text{M}$  concentrations.



### Signature Library 35

Formats	Supplementary Information
80 compounds per plate 0.1 mg; 1 mg; 2 mg dry film/powder 0.1 $\mu\text{mol}$ ; 1 $\mu\text{mol}$ DMSO solutions	EC <sub>50</sub> MTT test SL#35_MTT_Macrocycles.sdf

#### References:

1. *Nature Reviews Drug Discovery* 13, 588–602 (2014) doi:10.1038/nrd4366.
2. *Gastroenterol Rep (Oxf)*. 2015 Nov; 3(4): 269–276 doi:10.1093/gastro/gov046

#### Contact us:

USA: +1 336 721 1617  
Japan: +81-80-3401-9097  
Europe/Global:

[mparisi@asinex.com](mailto:mparisi@asinex.com)  
[sota@asinex.com](mailto:sota@asinex.com)  
[lsadovenko@asinex.com](mailto:lsadovenko@asinex.com)